Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on
"Dr. Reddy's partners with FUJIFILM and Global Response Aid for Avigan (favipiravir), a potential treatment
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, | AMIT AGARWAL | APARNA TEKURI |
| Hyderabad - 500034. Telangana, India. | amita@drreddys.com | aparnatekuri@drreddys.com |
| (Ph: +91-40-49002135) | (Ph: +91-40- 49002446) |
partners with FUJIFILM and Global Response Aid for Avigan (favipiravir), a potential treatment of COVID-19
Hyderabad, India, July 01, 2020 - Dr. Reddy's Laboratories Ltd.
(BSE: 500124, NSE: DRREDDY, NYSE: RDY, hereafter referred to as "Dr. Reddy's") announces partnering with FUJIFILM
Corporation through FUJIFILM Toyama Chemical Co. Ltd. (hereafter referred to as "FUJIFILM") and Global Response Aid
(hereafter referred to as "GRA") for the development, manufacture and sales of Avigan Tablets (generic name: favipiravir),
a potential treatment of COVID-19.
Under the tripartite agreement
signed on 30th June 2020, FUJIFILM grants Dr. Reddy's the exclusive rights of manufacturing and also grants both
Dr. Reddy's and GRA the rights to develop, sell and distribute Avigan in all countries other than Japan,
China and Russia. Dr. Reddy's would have exclusive rights for development, selling and distribution of Avigan in India.
Further, FUJIFILM would receive an upfront license fee and royalties on sales from Dr. Reddy's and GRA.
FUJIFILM will provide Dr. Reddy's and GRA with an array
of data on Avigan 's preclinical and clinical studies that FUJIFILM has accumulated thus far. Dr. Reddy's and GRA
will use this data for clinical studies targeting COVID-19 in regions where infection has been spreading. In addition, FUJIFILM
will grant Dr.Reddy's right to use Avigan 's patents of formulation and manufacturing method. Dr. Reddy's
will herewith establish a setup for manufacturing drugs of the same quality as Avigan , and utilize GRA's global sales
network to supply the manufactured drugs swiftly and in a stable manner.
The FUJIFILM Group is currently conducting a clinical study
on Avigan targeting COVID-19 patients in Japan and the US, and is working to increase the drug's production by partnering
with domestic and overseas companies. Dr. Reddy's and GRA shall introduce the product in the market post all applicable approvals
in the respective countries.
About Avigan Tablets
Avigan Tablet, developed by FUJIFILM Toyama Chemical, was
approved for manufacture and sale in Japan in 2014 as an influenza antiviral drug. The drug is to be considered for use only when
there is an outbreak of novel or re-emerging influenza virus infections in which other influenza antiviral drugs are either not
effective or insufficiently effective, and the Japanese government decides to use the drug as a countermeasure against such influenza
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd.
(BSE: 500124, NSE: DRREDDY, NYSE: RDY, hereinafter "Dr. Reddy's") is an integrated pharmaceutical company, committed
to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &
Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including
APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus
are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets
across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,
log on to: www.drreddys.com
About FUJIFILM Corporation, Tokyo, Japan is one of the
major operating companies of FUJIFILM Holdings Corporation. The company brings cutting edge solutions to a broad range of global
industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation.
Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials,
optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical,
mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of
$21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good
corporate citizenship. For more information, please visit: holdings.fujifilm.com
About Global Response Aid
Global Response Aid (hereinafter "GRA"), based in Dubai, provides solutions to public health challenges. GRA was established
by global logistics leader Agility to procure and develop certified diagnostic, testing and protective products and services used
in the detection, treatment and prevention of COVID-19 and other public health threats. GRA works with trusted manufacturers to
source safe, effective products for governments, health authorities and public institutions; frontline medical facilities; NGOs;
and companies looking to safeguard workers and workplaces. GRA-sourced products include ventilators, thermal detection equipment,
thermometers, masks, goggles, protective suits, nitrile gloves, cleaning and sanitation supplies, and point-of-care test kits.
GRA's mobile phone app helps stop the spread of viruses through the use of community-driven contact tracing and alerts. GRA also
deploys Mobile Diagnostic Testing Vehicles and trained teams that perform COVID-19 testing at schools and workplaces. For more
information, please visit https://globalresponseaid.com/
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the
words "may", "will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements
due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency
exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and
in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration
issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products
and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including
coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange
Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our
Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained